Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204917 · ClinicalTrials.gov registry record · Phase 1
CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children
A Phase 1 study of Vesico-Ureteral Reflux, sponsored by Kassa Darge.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT02204917 is a Phase 1 study of Vesico-Ureteral Reflux that has completed, run by Kassa Darge. The registered enrollment target is 31 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02204917, a Phase 1 study of Vesico-Ureteral Reflux, has completed, sponsored by Kassa Darge.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
In this clinical trial the investigators aim to evaluate the diagnostic feasibility and safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and urethral imaging in children.
Conditions Studied
Interventions
- DRUG OPTISON
Study Locations (1)
Pennsylvania
- Department of Radiology, the Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02204917
The ClinicalTrials.gov registry entry for NCT02204917 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kassa Darge, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vesico-Ureteral Reflux appearing as the primary indexed condition, and to 1 intervention - of which OPTISON is the first listed.
NCT02204917 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02204917 about?
NCT02204917 is a clinical study titled "CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children". In this clinical trial the investigators aim to evaluate the diagnostic feasibility and safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and urethral imaging in children.
What is the current status of trial NCT02204917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-07. Estimated completion is 2017-03.
What conditions does trial NCT02204917 study?
This clinical trial studies the following conditions: Vesico-Ureteral Reflux.
What interventions are being tested in trial NCT02204917?
The interventions under investigation include: OPTISON (DRUG).
Who is sponsoring clinical trial NCT02204917?
This trial is sponsored by Kassa Darge, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02204917 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.